Literature DB >> 15883689

Early invasive treatment (endarterectomy vs. stenting) of moderate-to-severe carotid stenosis in patients with transient ischaemic attack or minor stroke.

E Agostoni1, E Beghi, G Pappadà, R Marina, C Ferrarese.   

Abstract

Carotid endarterectomy (CA) is an effective treatment for the secondary prevention of stroke in patients with carotid stenosis >50%. More recently, carotid angioplasty with stenting (CAS) has been introduced and found to be effective in case series and small clinical trials. Although CAS has been shown not to be inferior to CA, the comparative effects of early treatment (i.e., during the first month after transient ischaemic attack (TIA) or minor stroke) with these techniques are unknown. Early treatment is advocated, as recurrent stroke tends to present frequently in this time period. On this background, we designed a randomised clinical trial comparing the efficacy and safety of CA vs. CAS in patients who had suffered TIA or minor stroke in the antecedent month. The study design and methods of this multicentre pragmatic randomised parallel-group open trial are presented here.

Entities:  

Mesh:

Year:  2005        PMID: 15883689     DOI: 10.1007/s10072-005-0401-1

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  2 in total

1.  Carotid artery stenting versus endarterectomy for treatment of carotid artery stenosis.

Authors:  Mandy D Müller; Philippe Lyrer; Martin M Brown; Leo H Bonati
Journal:  Cochrane Database Syst Rev       Date:  2020-02-25

2.  Does sex matter? Thirty-day stroke and death rates after carotid artery stenting in women versus men: results from the Carotid Revascularization Endarterectomy versus Stenting Trial (CREST) lead-in phase.

Authors:  Virginia J Howard; Jenifer H Voeks; Helmi L Lutsep; Ariane Mackey; Genevieve Milot; Albert D Sam; Meelee Tom; Susan E Hughes; Alice J Sheffet; Mary Longbottom; Jason B Avery; Robert W Hobson; Thomas G Brott
Journal:  Stroke       Date:  2009-02-10       Impact factor: 7.914

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.